August 28, 2020
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
From the National Cancer Institute
NCI, Cancer Research UK launch Cancer Grand Challenges partnership to support bold new ideas for cancer research
The National Cancer Institute (NCI), part of the National Institutes of Health, will partner with Cancer Research UK to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research. Through Cancer Grand Challenges, NCI and Cancer Research UK will seek novel ideas from multidisciplinary research teams from around the world that offer the potential to make bold advances in cancer research and improve outcomes for people affected by cancer.
Member/Center Highlights
Chakrapani named Director, Cleveland Center for Membrane and Structural Biology
The Case Comprehensive Cancer Center (Case CCC) extends congratulations to Sudha Chakrapani, PhD as she was recently appointed Director of the Cleveland Center for Membrane and Structural Biology (CCMSB).

Dr. Chakrapani is the Joseph T. Wearn, MD, University Professor in Medicine, Professor of Physiology and Biophysics, Director of the Cryo-Electron Microscopy Core at Case Western Reserve University (CWRU) School of Medicine, and member of the Case CCC's Developmental Therapeutics Program.
Luminary Therapeutics and CWRU enter formal collaboration for development of BAFF CAR
Reshmi Parameswaran
From The Daily: A novel BAFF target for use in CAR-T constructs, discovered by Reshmi Parameswaran, MS, PhD was recently included in a formal license agreement between Case Western Reserve University (CWRU) and Luminary Therapeutics.

Dr. Parameswaran is an assistant professor of pathology, pediatrics and medicine at CWRU School of Medicine and a member of the Case Comprehensive Cancer Center's Hematopoietic and Immune Cancer Biology Program.

Luminary intends to conduct IND-enabling non-clinical studies to support two clinical trials with its novel and proprietary non-viral autologous BAFF CAR-T (LMY-920) to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. This BAFF target is unique in that it binds to three distinct receptors (BAFF, BCMA, and TACI). Additionally, this BAFF target avoids early B-Cells while targeting more mature B-Cells that express one of three antigens.
Carraway to chair virtual program on hematologic malignancies
On Tuesday, September 8, Cleveland Clinic's Hetty Carraway, MD will chair a webinar with updates on hematologic malignancies from 5:30-7:00 pm ET, as part of the Institutional Perspectives in Cancer (IPC) series, presented by OncLive.

Topics will include polycythemia vera, chronic myelogenous leukemia, CAR-T and CAR-T therapy (non-lymphoma directed therapy). Webinar registration is complimentary.
VeloSano 7 fundraising continues through October 1
To-date, the 44 members that comprise Team Case Comprehensive Cancer Center have raised $19,882 and counting for lifesaving cancer research at Cleveland's top-tier hospitals and research institutions.

Despite the shift to Virtual VeloSano, our team pressed on and remained committed to participating in their chosen activities - biking, hiking, walking and yes, even gardening. Fundraising for this year's event will continue through October 1, 2020. Thank you to our committed team members, those who have donated to the cause and all who have cheered them on!
Algorithm developed by researchers at Case Western Reserve University, University of Akron used to predict local spread of COVID-19
Health officials in Cuyahoga County are using a mathematical model developed by researchers at Case Western Reserve University (CWRU) and the University of Akron (UA) to forecast the spread of SARS-CoV-2, the virus that causes COVID-19.

The research team, comprised of Daniela Calvetti, PhD, Johnie Rose, MD, PhD, and Erkki Somersalo, PhD of CWRU and Alexander Hoover, PhD of UA, uses census population and mobility data to model traffic and predict transmission of the virus, including transmission by infected-but-asymptomatic individuals. Dr. Rose is an assistant professor in the CWRU school of medicine and a member of the Case Comprehensive Cancer Center's Cancer Prevention, Control, & Population Research Program. The group, who has been collaborating on various COVID-19 projects since early April, recently published a paper detailing the model's theories and calculations in Frontiers in Physics (Calvetti, 2020, Front Phys).

These forecasts assist the Cuyahoga County Board of Health, local hospitals and other institutions in planning for the rise, and recent downturn, of new daily infections in the region.
University Hospitals selected as clinical trial site to test COVID-19 vaccine
Earlier this week, University Hospitals (UH) announced plans to be one of about 120 global clinical investigation sites participating in the Phase II/III study of an investigational vaccine, known as BNT162b2, recently given Fast Track designation by the US Food and Drug Administration (FDA).

The study site is sponsored by Pfizer Inc. and BioNTech SE and aims to enroll non-pregnant adults aged 18-85, with plans to ensure people of color, shown to be disproportionately affected by COVID-19, are well-represented in the study's enrollees.
Case CCC COVID-19 Resource Hub
As the COVID-19 outbreak progresses, the Case Comprehensive Cancer Center (Case CCC) has centralized COVID-19 related news, resources and funding opportunities for our cancer center community. Content is updated regularly.

To have a cancer-focused resource added to the page, please email
What's Coming Up
Mark Your Calendar
Portrait of Jennie Cullen
Cancer Center Seminar Series
Friday, September 11, 2020, 12p via Zoom
Each Fall and Spring, the Case Comprehensive Cancer Center (Case CCC) hosts an interdisciplinary seminar series addressing cutting-edge clinical, translational and basic research topics in cancer, held weekly each Friday at 12 pm EST. As of March 2020, these weekly seminars are held virtually via Zoom.

This series returns this Fall, beginning Friday, September 11 with Jennifer Cullen, PhD, MPH presenting, "History, Evolution, and Modern Opportunities in Cancer Population Sciences" on behalf of the Cancer Prevention, Control & Population Research Program. Dr. Cullen holds the The James T. Pardee - Carl A. Gerstacker Professorship in Cancer Research and is Associate Director for Cancer Population Sciences at the Case CCC.
VeloSano bike to cure logo
VeloSano Trainee Dream Experiment Awardee Symposium Thursday, September 17, 2020, 9a via Zoom
In 2019, the Case Comprehensive Cancer Center granted 8 trainees with VeloSano Trainee Dream Experiment Fellowships. Awardees will present their projects and outcomes to the cancer research community on Thursday September 17, 2020 at 9 am via Zoom.

Please join us via Zoom to see a brief presentation of their research projects and to ask questions. Click here to view a list of awardees and their projects.
White text that reads "Artificial Intelligence in Oncology Virtual Symposium October 19-20, 2020 Early Bird Registration Ends Tuesday, September 1" over a dark blue background with light blue digits of code overlaying the background.
Early Bird Registration Ends Tuesday, Sept. 1: Artificial Intelligence in Oncology Virtual Symposium 2020
October 19-20, 2020

Registration cost for the second annual Artificial Intelligence in Oncology Symposium will increase after Tuesday, September 1, 2020. The symposium will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, drug discovery, and ethics and policy to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will take place virtually.

Join us for four focused sessions, with international speakers and panel discussions providing unique perspectives on how AI and machine learning are impacting the major areas of radiology, pathology and -omics in the contexts of precision medicine approaches for characterizing tumors and predicting therapeutic response.

Beyond the science, attendees will be able to network and enjoy a special session highlighting some of the brightest rising stars in the field of AI in oncology, selected from abstract submissions. Submit your abstract by Friday, September 11!

Geraldine McGinty, MD, MBA, FACR will present the symposium plenary, "Fostering a Strong Ecosystem for AI in Medical Imaging." Dr. McGinty is an internationally recognized expert in imaging economics, Chair of the American College of Radiology Board of Chancellors and Chief Strategy and Contracting Officer at Weill Cornell Medicine in New York City.

Additional keynotes in drug discovery, ethics & policy and pathology will be delivered by Russ Altman, MD, PhD of Stanford University, Aashima Gupta, MS of Google, Vinay Prasad, MD, MPH of the University of California, San Francisco, and Yinyin Yuan, PhD of the Institute of Cancer Research, London. Learn more about AIO 2020 speakers.
Case Western Reserve University Case Comprehensive Cancer Center Logo in dark CWRU blue
Case CCC Fall Clinical Research Retreat
October 28, 2020, 5-7p via Zoom
The Case Comprehensive Cancer Center's Fall Clinical Research Retreat will be held virtually on October 28, 2020 from 5-7 pm.

The retreat theme is, "Immunotherapy in Cancer Research." The retreat will include a presentation by Leland Metheny, MD, Chair of the Case CCC Protocol Review and Monitoring Committee (PRMC) and a keynote presentation from Timothy Chan, MD, PhD, Director of Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

Registration is required.
Additional Upcoming Events
NCCN Oncology Policy Virtual Summit
September 9, 2020
The Summit will explore diverse perspectives related to emerging models to drive down healthcare costs in the United States and their potential impact on access to high-quality cancer care. Major themes of the summit will include an overview of legislative and regulatory efforts to reduce health costs, the current state of value-based payment models, and the impact of these models on providers and patients with cancer. The summit will also explore the unique implications of policies intended to curb costs for rural and other underserved populations.

If you have any questions, please contact Terrell Johnson, Manager, Policy and Advocacy,
NCCN 2020 Virtual Congress: Hematologic Malignancies
October 9-10, 2020
Attend this NCCN virtual congress to hear from world-renowned experts in the management of Hematologic Malignancies present the latest treatment advances, updates to the standard of care as recommended in the NCCN Guidelines®, and unique and challenging patient cases.

Co-chaired by Ranjana H. Advani, MD, Stanford Cancer Institute, and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, this virtual program features presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematological malignancies.

This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
NCCN 2021 Annual Conference: Call for Abstracts
Abstract Deadline: November 11, 2020
NCCN is now accepting abstracts for consideration to be presented during the NCCN 2021 Annual Conference General Poster Session at the Rosen Shingle Creek in Orlando, Florida on Thursday, March 18 and Friday, March 19, 2021. NCCN welcomes original abstracts from investigators in the general oncology community. Submissions will be accepted from academic institutions, teaching and community hospitals, or industry. Both NCCN and non-NCCN institutions may participate.

Research may fall into the general areas below:

  • Clinical Oncology (all phases)
  • Pre-Clinical Oncology
  • Epidemiology/Risks/Prevention
  • Correlative/Genomic
  • Best Practices in Implementation and Use of Clinical Practice Guidelines
  • Quality Improvement
  • Outcomes and Health Services Research
  • Bioinformatics/Information Technology Sciences
Sixth Computational Approaches for Cancer Workshop (CAFCW20)
Abstract Deadline: September 6, 2020
Workshop: November 13, 2020
The National Cancer Institute Center for Biomedical Informatics and Information Technology and SC20 are seeking abstracts for presentations for the Sixth Computational Approaches for Cancer Workshop (CAFCW20). CAFCW20 is a workshop designed to bring together clinicians, cancer biologists, mathematicians, data scientists, computational scientists, engineers, developers, thought leaders, and anyone else interested in advancing computation to use in cancer care and research. This year’s topic is “AI and HPC: Overcoming Data Challenges in Cancer Research and Clinical Applications.”

A special emphasis for the CAFCW20 is the role of HPC and AI to address research challenges when data are limited by availability, variability and size. The workshop will be held in conjunction with SC20: The International Conference on High Performance Computing, Networking, Storage and Analysis in Atlanta, GA., on November 15.
SGO 2021 Annual Meeting
Abstract Deadline: October 23, 2020
Annual Meeting: March 20-23, 2021

The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer is a comprehensive forum for the subspecialty of gynecologic oncology. Whether you’re a physician, surgeon, researcher, allied health professional or a student in the field, you can join us to make the connections that will boost your career, see what’s new in gynecologic oncology science and research, and learn the best practices and techniques that can take your care to the next level.

The Call for Abstracts and Surgical Films for the SGO 2021 Annual Meeting on Women’s Cancer is open through October 23, 2020. Call for Late-breaking abstracts will be open December 1, 2020 through January 4, 2021.
Funding Opportunities
Deadline: Monday, August 31, 2020

The Case Comprehensive Cancer Center is now accepting applications for the Fall 2020 pilot funding opportunities:

  • Available award: $120,000 for one year

  • Available award: $75,000 for 18 months

  • Available award: $180,000 for 18 months

Questions? Contact or Julie DeJager Glavic at 216.368.5780.
Proposals accepted on rolling basis subject to funds availability

The Case Comprehensive Cancer Center (Case CCC) has budgeted funds for the conduct of early phase clinical trials of relatively short duration. The objectives are to identify and fund investigator-initiated trials, which meet the Cancer Center Support Grant and Case CCC requirements, entertain highly innovative and novel ideas, and which directly foster the mission of the Case CCC. These may be new trials under development or an existing investigator-initiated trial that is unfunded/underfunded. Priority will be given to trials that have been developed jointly between investigators at both hospital systems (University Hospitals and Cleveland Clinic), with planned accrual at both sites.
The NCI has announced a Request for Applications for the Predoctoral to Postdoctoral Fellow Transition (F99/K00) Award for 2020, to support outstanding PhD candidates as they complete their dissertation research training (F99 phase; 1-2 years) and transition to a mentored, cancer-focused postdoctoral career development research positions (K00 phase – up to 4 years).

The F99/K00 award is open to 3rd or 4th year PhD students, including F31 Fellowship applicants and current awardees (note that 3 rd or 4 th year students would have matriculated in 2017 or 2018). International students may also apply. Students Matriculated in a dual-degree program (e.g.) MD/PhD, DO/PhD, DDS/PhD, or DVM/PhD) are not eligible for the F99/K00 program. Projects must be clearly focused on cancer.

To apply for this award, an applicant must be nominated by their institution. As each institution is allocated only one nomination, the Case Comprehensive Cancer Center (Case CCC) requires potential applicants to assemble a pre-application.

Click here to download nomination application instructions. Contact Damian Junk at for additional information.
VeloSano logo
With the generous support from VeloSano Bike to Cure, the Case Comprehensive Cancer Center (Case CCC) is providing funding for Case CCC Trainee Associate Members to perform their “dream experiment.”

The experiment should catalyze highly innovative and impactful projects and help strengthen fellowship and career development grant applications. The intent of the award is to support a single or limited set of innovative experiments, not for general laboratory supplies/projects or maintenance of the trainee’s project.

Up to five (4) projects will be funded at $10,000/award. Research projects must be completed within one (1) year, with funds expended by June 30, 2021.
CTSC logo
The Clinical and Translational Pilot Award Program is funded through the NIH National Center for Advancing Translational Sciences, which defines translation as “the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioral changes.” ( The program is a component of the UL1 TR002548 Clinical and Translational Science Awards from the National Institute of Health (NIH).

  • Up to six grants will be awarded with budgets limited to $50,000 in direct costs. 
  • Research proposed in the application must be accomplished by April 30, 2022.
  • Carry-over of funds is not permitted.

COVID-related research is excluded from this opportunity due to the previous COVID funding opportunity released in July 2020.

Annual Pilots will be prioritized for projects that have the potential for moving ideas and/or technologies towards patients.  This includes drug and device development, interventions, and research methods and processes in the translational space, including implementation science.
The Department of Defense and its Congressionally Directed Medical Research Programs (CDMRP) have announced program details and application instructions for the following FY2020 Programs:

  • Prostate Cancer Pathology Resource Network Award

  • Concept Award
  • Idea Development Award
  • Resource and Community Development Award

  • Clinical Research Nurse Development Award (NEW!)

  • Breakthrough Award Levels 1 and 2
  • Era of Hope Scholar Award
In The News
Crain's Cleveland Business - August 23, 2020
"And yet what is bringing the world to a standstill now? It's a biological question," said Timothy Chan, MD, PhD, director of the Cleveland Clinic's Center for Immunotherapy and Precision Immuno-Oncology. "Whether it's cancer, infectious disease or other biological challenges, "it's really clear that human health and disease and specifically translational immunology is very, very important." Dr. Chan is Co-Director of the National Center for Regenerative Medicine and member of the Case CCC's Hematopoietic and Immune Cancer Biology Program.
Times of India - August 26, 2020
A recently funded project by Satish Viswanath, PhD and Pallavi Tiwari, PhD is focused on developing AI and radiomics tools for cancer research. Drs. Viswanath and Tiwari are assistant professors of biomedical engineering at the Case School of Engineering and members of the Case CCC's Cancer Imaging Program.
From The NIH
Weekly NIH Funding Opportunities and Notices

Funding Opportunities

Deadline: January 4, 2021

Deadline: January 4, 2021

Deadline(s): October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022

Deadline: November 09, 2020

Deadline: November 9, 2020

Deadline: November 18, 2020
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.